GeneReach Biotechnology Valuation
Is 4171 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4171?
Other financial metrics that can be useful for relative valuation.
|What is 4171's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 4171's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
4116 BenQ Medical Technology
6796 Medimaging Integrated Solution
1733 Apex Biotechnology
4171 GeneReach Biotechnology
Price-To-Earnings vs Peers: 4171 is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (19.6x).
Price to Earnings Ratio vs Industry
How does 4171's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price to Earnings Ratio vs Fair Ratio
What is 4171's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||7.2x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4171's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 4171 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4171 (NT$53.1) is trading below our estimate of fair value (NT$767.11)
Significantly Below Fair Value: 4171 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.